Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from DXCM

Dow Jones Futures Rise, Yields Slide Ahead Of Key Economic Data; AI Stock Soars Into Buy Zone

The stock market rally rebounded bullishly Thursday despite Treasury yields racing above 4% and Tesla retreating. C3.ai stock spiked late.

Investors Business Daily

IBD Live Q&A And Two Key Stock Lists For March 2, 2023

Welcome to IBD Live! This list of FAQs and useful links will speed your learning curve. Some users have reported the inability to access the IBD Live show page on investors.com from their mobile and tablet devices. Please clear your browser cache and relaunch the browser to resolve this issue.…

Investors Business Daily

Deere Leads 5 Stocks With Hot Products Near Buy Points

Deere, fresh off Friday's strong earnings move, leads this weekend's watch list of 5 stocks near buy points.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Dow Jones Futures Fall In Resilient Market Rally; Tesla Stock Falls On Production Cut

Futures fell after the S&P 500 retook key levels last week. Oil prices rose. Tesla stock fell on China production cut reports.

Investors Business Daily

Dexcom Leads 5 Stocks Near Buy Points

Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals.

Investors Business Daily

Dow Jones Futures Rise: 5 Stocks Near Buy Points In Market Rally; Tesla FSD Beta Expands Widely

The S&P 500 still faces its 200-day line with key economic data looming. Tesla FSD Beta gets a wide release after TSLA stock jumped from bear market lows.

Investors Business Daily

Dow Jones Futures: Apple Holds, Amazon Joins Megacap Meltdown; What To Do Now

Apple dipped after the iPhone giant topped views. Amazon crashed on guidance, joining the megacap earnings meltdown.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

This Is What Whales Are Betting On DexCom

Someone with a lot of money to spend has taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 20.9% on an annualized basis producing an average annual return of 27.35%. Currently, DexCom has a market capitalization of $30.77 billion.

Benzinga

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $16,000 Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 64.52% on an annualized basis producing an average annual return of 74.42%. Currently, DexCom has a market capitalization of $115.32 billion.

Benzinga

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 22.06% on an annualized basis producing an average annual return of 28.95%. Currently, DexCom has a market capitalization of $29.24 billion.

Benzinga

What Are Whales Doing With DexCom

A whale with a lot of money to spend has taken a noticeably bearish stance on DexCom. Looking at options history for DexCom (NASDAQ:DXCM) we detected 25 strange trades.

Benzinga

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter. According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

Benzinga

DexCom Earnings Perspective: Return On Invested Capital

Pulled from Benzinga Pro data, DexCom (NASDAQ:DXCM) posted Q1 earnings of $97.30 million, an increase from Q4 of 601.55%. Sales dropped to $628.80 million, a 9.94% decrease between quarters.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

If You Invested $1000 In DexCom 10 Years Ago, Here's How Much You Would Have Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 10 years by 32.66% on an annualized basis producing an average annual return of 44.4%. Currently, DexCom has a market capitalization of $39.95 billion.

Benzinga

Read Here Why Did This Analyst Cut DexCom's Price Target

Benzinga

Here's How Much $100 Invested In DexCom 5 Years Ago Would Be Worth Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 32.15% on an annualized basis producing an average annual return of 45.92%. Currently, DexCom has a market capitalization of $49.71 billion.

Benzinga

Dexcom G7 Continuous Glucose Monitoring System Receives European CE Mark

DexCom Inc's (NASDAQ: DXCM) Dexcom G7 Continuous Glucose Monitoring (CGM) System has

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

DexCom Stock Falls As Q4 Profit, FY22 Sales Outlook Trail Wall Street Estimates

DexCom Inc's (NASDAQ: DXCM)

StockNews.com

2 Upgraded Diabetes Stocks to Add to Your Watchlist

Diabetes has become one of the leading causes of death for Americans, claiming more than 100,000 lives in 2021. But the disease’s prevalence represents promising prospects for the diabetes care devices market. Given this backdrop, analysts have recently upgraded diabetes stocks DexCom (DXCM) and Insulet (PODD). Thus, these stocks could…

Benzinga

Will Chart Analysts Notice Bad Omen on DexCom's Chart

If history is any guide, there may be trouble ahead for shares of DexCom (NASDAQ:DXCM). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

What 5 Analyst Ratings Have To Say About DexCom

Analysts have provided the following ratings for DexCom (NASDAQ:DXCM) within the last quarter:

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.